Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Biased agonism and polymorphic variation at the GLP-1 receptor: Implications for the development of personalised therapeutics

22 Aug 2022

Abstract excerpt

Glucagon-like peptide-1 receptor (GLP-1R) is a well-studied incretin hormone receptor and target of several therapeutic drugs for type 2 diabetes (T2D), obesity and, more recently, cardiovascular disease. Some signalling pathways downstream of GLP-1R may be responsible for drug adverse effects such as nausea, while others mediate therapeutic outcomes of incretin-based T2D therapeutics. Understanding the interplay...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Diabetes Treatment and Management
Share to Neuropeptides and Animal Physiology
Share to Receptor Mechanisms and Signaling

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 36007775
DOI: 10.1016/j.phrs.2022.106411

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Biased agonism and polymorphic variation at the GLP-1 receptor: Implications for the development of personalised therapeuticsPMID 36007775Read ↗

Minireview: Signal bias, allosterism, and polymorphic variation at the GLP-1R: implications for drug discovery.Semantic proximity Read ↗

The GLP-1R as a model for understanding and exploiting biased agonism in next-generation medicinesSemantic proximity Read ↗

Genetic variations in GLP-1R: Impact on diabetes and obesity therapeutics.Semantic proximity Read ↗

Global glucagon-like peptide-2 receptor activation linked to increased obesity risk in the UK Biobank.Semantic proximity Read ↗

Modelling G protein-biased agonism using GLP-1 receptor C-terminal mutations.Semantic proximity Read ↗

Pharmacogenomics of GLP-1 Receptor Agonists: Precision Medicine in the Age of Ozempic and MounjaroSemantic proximity Read ↗

Human GLP1R variants affecting GLP1R cell surface expression contribute to impaired glucose control and increased adipositySemantic proximity Read ↗

Characterizing the role of extracellular domain in GLP-1R biased agonism.Semantic proximity Read ↗

Pharmacogenomics of GLP-1 Receptor Agonists: A genome wide analysis of observational data and large randomized controlled trialsSemantic proximity Read ↗

Differential impact of amino acid substitutions on critical residues of the human glucagon-like peptide-1 receptor involved in peptide activity and small-molecule allostery.Semantic proximity Read ↗

Biased signaling in naturally occurring mutations of G protein-coupled receptors associated with diverse human diseases.Semantic proximity Read ↗

Ligand-independent modulation of GIPR signaling by splice variantsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.